- Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
For: Rheumatoid ArthritisUnited States · Argentina · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
This study looks at how safe and effective a drug called Upadacitinib is over a long time for people with Crohn's disease. It checks if the drug helps people feel better and if they stay better, as well as any side effects.
For: Crohn's Disease (CD)Slovakia · Netherlands · France - RecruitingPHASE3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
This study looks at a daily tablet called upadacitinib for severe alopecia areata, a condition where your immune system attacks hair follicles, causing hair loss. It aims to see how safe and effective it is for teenagers and adults.
For: Alopecia AreataUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study looks at combining two medicines, vedolizumab and upadacitinib, for adults with moderate to severe Crohn's Disease. It aims to see if this combination better reduces bowel inflammation and ulcers compared to vedolizumab alone, and to check its safety.
For: Crohn's DiseaseUnited States · Austria · Belgium - Active not recruitingPHASE3
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
This study looks at a new combination treatment for teenagers and adults with moderate to severe eczema. It combines a new tablet called upadacitinib with steroid creams to see how well it works and if it's safe.
For: Atopic DermatitisUnited States · Australia · Austria - RecruitingPHASE3
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Upadacitinib for children and teenagers with Crohn's disease. It's for those whose current treatments aren't working well. We want to see if it's safe and helps them feel better.
For: Crohn's DiseaseUnited States · Australia · Belgium - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study looks at two medicines, upadacitinib and dupilumab, for children aged 2 to 11 with moderate to severe eczema (atopic dermatitis). It wants to see which one works better and has fewer side effects for children who need strong treatment.
For: Atopic DermatitisUnited States · Argentina · Australia - RecruitingPHASE3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
This study looks at new treatments for a severe type of childhood arthritis called Systemic Juvenile Idiopathic Arthritis (sJIA). It compares upadacitinib with an existing treatment, tocilizumab, to see how well they work and if they cause any side effects in children aged 1 to 17.
For: Juvenile Idiopathic ArthritisUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
This study is testing a new medicine, Upadacitinib, for adults with a type of arthritis called axial spondyloarthritis. It's comparing the medicine to a dummy pill to see if it helps reduce pain and stiffness, and if it's safe to use.
For: Axial SpondyloarthritisGermany · France · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
This study is testing a new medicine, upadacitinib, for people aged 18 and over with moderate to severe eczema (atopic dermatitis). They want to see how well it clears up skin, reduces itching, and improves quality of life over 16 weeks compared to a dummy pill.
For: Moderate and Severe Atopic DermatitisFrance · Estonia · Croatia - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis (Flex-Up)
This study looks at a medicine called Upadacitinib for adults with moderate to severe eczema. It wants to see how well it clears up skin symptoms and improves quality of life. The study compares different ways of giving the medicine.
For: Dermatitis atopicNetherlands · Spain · Portugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
This study is looking at a new medicine called Upadacitinib for teenagers and adults with moderate to severe eczema. It wants to see if the drug helps clear up skin and reduce itching better than a dummy pill.
For: Moderate and Severe Atopic DermatitisNetherlands · Denmark · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis
This study is testing a new medicine, upadacitinib, for giant cell arteritis (GCA). Researchers want to see if it can help people stay well and reduce the need for steroid medicines, comparing it to a dummy medicine.
For: Giant Cell ArteritisDenmark · Belgium · Germany - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
For: Rheumatoid ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
This study looks at a medicine called Upadacitinib for children and young people aged 2-17 with moderate to severe ulcerative colitis. It aims to see how safe and effective the medicine is, how it works in the body, and if it helps reduce symptoms.
For: Ulcerative ColitisUnited States · Australia · Belgium - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
For: Crohn's DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
For: Hidradenitis SuppurativaUnited States · Argentina · Australia